Hsbc Holdings PLC Clovis Oncology, Inc. Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.63 - $2.96 $32,723 - $153,748	-51,942 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $74,277 - $163,097	51,942 New	51,942 $132,000
Q3 2020 Nov 12, 2020	SELL	$4.82 - $7.72 $49,241 - $78,867	-10,216 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $58,129 - $98,993	10,216 New	10,216 $69,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $128,646 - $704,551	-42,882 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $168,526 - $658,238	42,882 New	42,882 $169,000
Q4 2018 Feb 13, 2019	SELL	$11.63 - $32.67 $383,359 - $1.08 Million	-32,963 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$29.37 - $49.48 $968,123 - $1.63 Million	32,963 New	32,963 $968,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.